ALK and non-small cell lung carcinoma: Across studies, sample sizes ranged from 637 to 1,013 participants, predominantly involving patients with metastatic or recurrent NSCLC without EGFR or ALK alterations and with Eastern Cooperative Oncology Group (ECOG) performance status 0-1.